Clariane (CLARI) AI Stock Analysis

• Market Cap: €1.67B
• Dividend Yield: N/A
• Average Volume (3M): 587.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 1.98%
• EPS Growth: 85.87%
• Country: FR
• Employees: 61,798
• Sector: Consumer Defensive
• Sector Strength: 60
• Industry: Medical - Care Facilities
• EPS (TTM): -0.16
• Shares Outstanding: 356,754,460
• 10 Day Avg. Volume: 364,746
• 30 Day Avg. Volume: 587,394
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €4.67
• Price Target Upside: -2.10% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 57 Neutral
• Price Target: €4.50 ▼(-5.66% Downside)

Korian SA's overall stock score is primarily influenced by its strong operational efficiencies and cash flow management. However, the negative valuation metrics and bearish technical indicators significantly impact the score. The absence of earnings call insights and corporate events leaves these areas neutral.

Clariane Business Overview & Revenue Model

Company Description

Clariane (CLARI) is a forward-thinking company focused on the health and wellness sector, specializing in innovative solutions that enhance patient care and streamline healthcare processes. The company develops and offers a range of products and services, including digital health platforms, telemedicine services, and health data analytics tools, aimed at improving the efficiency and effectiveness of healthcare delivery. Clariane is committed to leveraging technology to empower both healthcare providers and patients, ensuring better outcomes and enhanced accessibility to medical resources.

How the Company Makes Money

Clariane generates revenue through multiple channels, including subscription fees from healthcare providers for access to its digital health platforms, transaction fees from telemedicine consultations, and licensing fees for its health data analytics tools. Additionally, the company has formed strategic partnerships with various healthcare institutions and technology firms, which not only bolster its market presence but also create collaborative revenue opportunities. These partnerships often involve joint ventures or co-development agreements, allowing Clariane to expand its offerings and tap into new customer bases, further contributing to its overall earnings.

Clariane Financial Statement Overview

Summary

Korian SA demonstrates strong operational efficiencies and cash flow management, with consistent revenue growth. However, profitability challenges and high leverage pose potential risks.

Income Statement

Korian SA has shown consistent revenue growth with a compound annual growth rate over the past five years. Despite recent net losses, the company maintains healthy gross and EBIT margins, indicating operational efficiency. The net profit margin remains negative due to the net losses, which impacts overall profitability.

Balance Sheet

The company's balance sheet reflects a high debt-to-equity ratio, suggesting significant leverage, which could pose risks if not managed properly. However, the equity ratio is stable, indicating a sound asset base. Return on equity has been under pressure due to recent net losses, which affects investor returns.

Cash Flow

Korian SA has demonstrated strong cash flow generation capabilities, with rising operating cash flow and positive free cash flow growth. The operating cash flow to net income ratio is robust, highlighting efficient cash flow management. However, the free cash flow to net income ratio is impacted by the net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.28B	5.00B	4.44B	4.14B	3.77B
Gross Profit	4.84B	1.57B	4.09B	3.83B	3.48B
EBITDA	1.01B	907.48M	907.45M	841.76M	760.02M
Net Income	-55.12M	-105.25M	22.06M	91.11M	39.40M
Balance Sheet
Total Assets	14.26B	15.18B	14.57B	14.31B	13.20B
Cash, Cash Equivalents and Short-Term Investments	518.10M	677.91M	734.35M	1.22B	1.16B
Total Debt	7.98B	8.55B	8.27B	8.23B	7.71B
Total Liabilities	10.24B	11.24B	10.71B	10.54B	9.87B
Stockholders Equity	3.69B	3.58B	3.54B	3.49B	3.16B
Cash Flow
Free Cash Flow	600.10M	309.05M	116.36M	311.05M	274.67M
Operating Cash Flow	908.13M	804.15M	681.66M	839.97M	794.77M
Investing Cash Flow	47.69M	-669.52M	-770.26M	-825.28M	-1.10B
Financing Cash Flow	-1.11B	-193.61M	-370.09M	31.38M	1.11B

Clariane Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.77
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CLARI, the sentiment is Positive. The current price of 4.77 is above the 20-day moving average (MA) of 4.60, below the 50-day MA of 4.79, and above the 200-day MA of 3.43, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 51.58 is Neutral, neither overbought nor oversold. The STOCH value of 84.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:CLARI.

Clariane Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNA	70 Outperform	€323.03M	14.53	7.12%	4.22%	9.58%	-6.69%
Sector *	63 Neutral	$20.95B	14.50	-4.08%	3.12%	2.72%	-11.24%
CLARI	57 Neutral	€1.67B	―	-1.70%	―	1.98%	85.87%
GDS	55 Neutral	€1.10B	―	-6.74%	―	5.79%	-575.58%
EMEIS	51 Neutral	€2.28B	0.02	-22.82%	―	8.43%	-102.06%